In the ever-evolving landscape of drug discovery, Zifo Technologies, through its expert Sujeegar Jeevanandam, sheds light on the transformative power of artificial intelligence (AI) in biopharma. Contrary to the belief that AI primarily leads to groundbreaking discoveries, Sujeegar emphasizes that its true strength lies in optimizing research processes and enhancing scientific outcomes with practical applications.
A recent survey conducted by Zifo exposes a significant challenge within the biopharma industry – a mere one in three scientists feel adept at utilizing scientific data for AI purposes, underscoring a critical need for enhanced data readiness. Despite the industry’s cautious approach towards technology integration, Sujeegar challenges the notion of biopharma being risk-averse, stating that embracing risks is inherent to the industry’s ethos given the uncertainties in clinical trials.
According to Sujeegar Jeevanandam, AI’s impact is not about sudden breakthroughs but rather about consistent value addition. Even a modest 5% enhancement at various stages of the drug development pipeline could result in substantial cost savings amounting to millions or billions. Beyond the acceleration of discovery timelines, AI’s true potential lies in simplifying mundane tasks, such as swiftly accessing pertinent information or guiding researchers to the exact location of required data, thereby streamlining operations and driving efficiencies.
Addressing privacy concerns and the apprehensions of scientists regarding AI expertise, Sujeegar suggests that making AI user-friendly will enhance its adoption rates. He emphasizes that scientists need not become AI experts but should be able to easily leverage its capabilities for improved productivity and outcomes. As the rate of AI adoption surpasses previous technological revolutions in the biopharma sector, Sujeegar stresses that all stakeholders, from lab personnel to top executives, must proactively integrate AI into their workflows to stay competitive in the evolving landscape.
Key Takeaways:
– AI in biopharma focuses on enhancing research processes and scientific outcomes rather than just revolutionary discoveries.
– The industry faces challenges in data readiness for AI applications, indicating a need for upskilling in utilizing scientific data effectively.
– Even marginal improvements at various stages of drug development through AI can lead to substantial cost savings.
– Simplifying the integration of AI into workflows is crucial for maximizing its benefits across all levels of biopharma organizations.
Tags: biopharma, biotech
Read more on finanznachrichten.de